2021 共识建议：玻璃体视网膜淋巴瘤的诊断

2021-05-19 国外肿瘤科相关专家小组（统称） Ocul Immunol Inflamm.2021 May 19;1-14.

玻璃体视网膜淋巴瘤（VRL）以前成为原发性眼内淋巴瘤，是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。

中文标题：

英文标题：

Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2021-05-19

简要介绍：

玻璃体视网膜淋巴瘤（VRL）以前成为原发性眼内淋巴瘤，是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=471821c0021133a9, title=2021 共识建议：玻璃体视网膜淋巴瘤的诊断, enTitle=Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma, guiderFrom=Ocul Immunol Inflamm.2021 May 19;1-14., authorId=0, author=, summary=玻璃体视网膜淋巴瘤（VRL）以前成为原发性眼内淋巴瘤，是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。, cover=https://img.medsci.cn/2021618/1623989999954_2020535.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Wed May 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>玻璃体视网膜淋巴瘤（VRL）以前成为原发性眼内淋巴瘤，是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=412, guiderKeyword=淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13462, appHits=131, showAppHits=0, pcHits=1344, showPcHits=13331, likes=1, shares=12, comments=7, approvalStatus=1, publishedTime=Fri Jun 18 13:15:45 CST 2021, publishedTimeString=2021-05-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Jun 18 12:20:14 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:45:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 共识建议：玻璃体视网膜淋巴瘤的诊断.pdf)])

2021 共识建议：玻璃体视网膜淋巴瘤的诊断.pdf

下载请点击：

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
2022-03-30 139ef189m47暂无昵称

学习了！

79 0
[GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
2021-10-28 245462683

学习学习

86 0
[GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
2021-09-21 ms8000000444017043

学习学习

117 0
[GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
2021-07-30 眼科芳

收益

140 0
[GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
2021-07-30 站在未来看现在

受益了

111 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2021 共识建议：玻璃体视网膜淋巴瘤的诊断

相关指南

拓展阅读

科室

工具

服务